Search results

623 results

Sorted by Relevance . Sort by Date

In development Remove In development filter
Proposed Remove Proposed filter
Technology appraisal guidance Remove Technology appraisal guidance filter

Ibrutinib with corticosteroids for untreated chronic graft versus host disease [ID3792]

Proposed [GID-TA10722] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Asciminib for treating chronic myeloid leukaemia after 2 or more tyrosine kinase inhibitors [ID3813]

Proposed [GID-TA10691] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Selinexor for treating unresectable dedifferentiated advanced liposarcoma [ID3825]

Proposed [GID-TA10694] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Retifanlimab for treating advanced anal canal squamous cell carcinoma after platinum-based chemotherapy [ID3815]

Proposed [GID-TA10698] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Etranacogene dezaparvovec for treating haemophilia B [ID3812]

Proposed [GID-TA10699] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Tralokinumab for treating moderate to severe atopic dermatitis in people aged 12 and over [ID3823]

Proposed [GID-TA10702] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Eptinezumab for preventing migraine [ID3803]

Proposed [GID-TA10677] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Gefapixant for treating refractory chronic cough [ID3789]

Proposed [GID-TA10678] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Remimazolam for general anaesthesia [ID3796]

Proposed [GID-TA10679] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Eladocagene exuparvovec for treating aromatic L-amino acid decarboxylase deficiency [ID3791]

Proposed [GID-TA10680] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Valoctocogene roxaparvovec for treating severe haemophilia A [ID3806]

Proposed [GID-TA10682] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Baloxavir marboxil for influenza prophylaxis in people aged 12 and over [ID3793]

Proposed [GID-TA10684] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Baloxavir marboxil for treating influenza in people at high risk of complications [ID3794]

Proposed [GID-TA10683] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Palbociclib for treating high-risk early breast cancer after neoadjuvant chemotherapy [ID3846]

Proposed [GID-TA10723] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Daratumumab in combination for untreated multiple myeloma when high-dose chemotherapy with stem cell transplant is unsuitable [ID3843]

Proposed [GID-TA10726] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Netarsudil for treating open angle glaucoma or ocular hypertension [ID1078]

Proposed [GID-TA10431] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Sarizotan for the treatment of respiratory symptoms associated with Rett syndrome [ID1506]

Proposed [GID-TA10662] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Nivolumab with ipilimumab for untreated PD-L1 positive unresectable or metastatic urothelial cancer [ID3829]

Proposed [GID-TA10707] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Rigosertib for previously treated high-risk myelodysplastic syndrome [ID805]

Proposed [GID-TA10709] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Imlifidase for preventing kidney transplant rejection in people with chronic kidney disease [ID1672]

Proposed [GID-TA10552] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Durvalumab with tremelimumab and chemotherapy for treating unresectable or advanced urothelial cancer [ID3855]

Proposed [GID-TA10748] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Azacitidine for treating relapsed or refractory angioimmunoblastic T-cell lymphoma [ID3864]

Proposed [GID-TA10750] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Atezolizumab for adjuvant treatment of resected non-small-cell lung cancer [ID3852 ]

Proposed [GID-TA10751] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Lifileucel for previously treated unresectable or metastatic melanoma [ID3863]

Proposed [GID-TA10752] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Nivolumab for adjuvant treatment of high-risk hepatocellular carcinoma after liver resection or ablation [ID3858]

Proposed [GID-TA10745] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Pembrolizumab with chemotherapy then olaparib maintenance for treating BRCA-negative advanced epithelial ovarian, fallopian tube or peritoneal cancer [ID3853]

Proposed [GID-TA10747] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Treosulfan with fludarabine for non-malignant disease before allogeneic stem cell transplant [ID1540]

Proposed [GID-TA10453] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Dulaglutide for treating type 2 diabetes [ID1451]

Proposed [GID-TA10439] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Gosuranemab for treating progressive supranuclear palsy [ID1607]

Proposed [GID-TA10553] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Autologous haematopoietic stem cell transplantation for treating multiple sclerosis (ID1111)

Proposed [GID-TA10306] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Atezolizumab in combination for advanced epithelial ovarian, fallopian tube or primary peritoneal cancer in people who have not received any prior systemic therapy [ID2700]

Proposed [GID-TA10574] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Olaparib with abiraterone for untreated hormone-relapsed metastatic prostate cancer [ID3920 ]

Proposed [GID-TA10802] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Amcenestrant for treating ER-positive, HER2-negative advanced breast cancer after hormonal therapy [ID3919]

Proposed [GID-TA10803] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after trastuzumab or a taxane [ID3909]

Proposed [GID-TA10804] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Tideglusib for treating congenital myotonic dystrophy type 1 [ID3915 ]

Proposed [GID-TA10791] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Mitapivat for treating pyruvate kinase deficiency [ID3914 ]

Proposed [GID-TA10795] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Maribavir for treating refractory or resistant cytomegalovirus infection after transplant [ID3900]

Proposed [GID-TA10792] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Tezepelumab for maintenance treatment of uncontrolled severe asthma in people aged 12 and over [ID3910]

Proposed [GID-TA10796] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Difelikefalin for treating pruritis in people having haemodialysis [ID3890 ]

Proposed [GID-TA10793] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Omecamtiv mecarbil for treating chronic heart failure with reduced ejection fraction [ID3912 ]

Proposed [GID-TA10797] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Brolucizumab for treating diabetic macular oedema [ID3902]

Proposed [GID-TA10794] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Faricimab for treating diabetic macular oedema [ID3899]

Proposed [GID-TA10798] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Faricimab for treating wet age-related macular degeneration [ID3898 ]

Proposed [GID-TA10799] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Imetelstat for treating relapsed or refractory transfusion-dependent myelodysplastic syndromes [ID3922]

Proposed [GID-TA10800] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Cemiplimab for treating recurrent or metastatic cervical cancer [ID3921]

Proposed [GID-TA10801] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Dapagliflozin for treating chronic kidney disease [ID3866]

Proposed [GID-TA10808] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Avatrombopag in combination for treating chronic immune thrombocytopenia [ID3838]

Proposed [GID-TA10738] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Olipudase alfa for treating Niemann-Pick disease types A and B [ID3913 ]

Proposed [GID-TA10788] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Timrepigene emparvovec for treating choroideremia [ID3916]

Proposed [GID-TA10787] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Pembrolizumab for adjuvant treatment of resected stage 2 melanoma with high risk of recurrence [ID3908 ]

Proposed [GID-TA10786] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed